Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO

Rank in Stocks #31794
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Share Price
$0.3541
Last synced: 2026-11-20
Market Cap
$2.39M
Change (1 day)
-4.30%
Change (1 year)
-69.99%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
EPS for Mustang Bio, Inc. (MBIO)
EPS as of September 2026 TTM: $-0.51
According to Mustang Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-0.51. At the end of 2025 the company had an EPS of $-0.39, an increase over its 2024 EPS of $-2.57.
EPS history for Mustang Bio, Inc. from 2015 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.51 30.77%
2025 $-0.39 -84.82%
2024 $-2.57 -57.17%
2023 $-6.00 -46.67%
2022 $-11.25 -1.32%
2021 $-11.40 -33.33%
2020 $-17.10 -14.63%
2019 $-20.03 17.34%
2018 $-17.07 -8.13%
2017 $-18.58 156.63%
2016 $-7.24 8.06%
2015 $-6.70 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -3,170.59%
US
$-7.07 1,286.27%
US
$-5.29 937.25%
AU
$12.73 -2,596.51%
BE
$21.56 -4,327.45%
NL

Questions about Mustang Bio, Inc.'s earnings per share (EPS)

What is Mustang Bio, Inc.'s earnings per share (EPS)?

Mustang Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-0.51, as of Sep 2026.

What was Mustang Bio, Inc.'s earnings per share (EPS) in 2025?

In 2025, Mustang Bio, Inc.'s earnings per share (EPS) was $-0.39, compared with $-2.57 in 2024.

How has Mustang Bio, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Mustang Bio, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.39) and lowest in 2020 ($-17.10).

How does Mustang Bio, Inc.'s earnings per share (EPS) compare with similar companies?

Mustang Bio, Inc.'s earnings per share (EPS) ($-0.51) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.